Computational Analysis of FDA-Approved Drugs for Potential Repurposing in Alzheimer’s Disease: Targeting mTOR and NGFR Pathways. Sci. Ess. J [Internet]. 2026 Jan. 5 [cited 2026 Oct. 23];42(1):50-7. Available from: https://ejournals.swu.ac.th/sej/article/view/17130